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Photodynamic therapy (PDT) mediated by Photofrin has recently
been approved as a therapeutic modality for specific types of
malignant tumours (Levy, 1996). This breakthrough further stimu-
lates research efforts aimed at developing more effective
phototherapeutic protocols, as well as at broadening the scope of
PDT and overcoming its present limitations. Thus, it is well
known (Dougherty, 1987) that PDT with Photofrin is essentially
ineffective in the treatment of heavily pigmented tumours, largely
owing to the strong absorbance of melanin in the 630-nm range,
i.e. at the wavelengths that are most frequently used to activate
Photofrin in clinical PDT; as a consequence, melanin inhibits any
significant light penetration into this type of neoplastic lesions
(Svaasand et al, 1990). Recent findings (Schuitmaker et al, 1995;
Biolo et al, 1996; Woodburn et al, 1997) show that an experimen-
tally implanted melanotic melanoma can be made to be responsive
to PDT when the irradiation is performed in the presence of
selected second-generation photosensitizing agents, such as
Si(IV)-naphthalocyanine, bacteriochlorin a and Lu(III)-texa-
phyrin; all of these photosensitizers are characterized by an
expanded macrocycle and high molar absorptivity in the 750–
800 nm spectral interval, where melanin exhibits a small residual
absorbance, thereby minimizing its optical filtering action
(Svaasand et al, 1990). The efficacy of the PDT treatment is
further enhanced if the melanosomes in the tumour are extensively
destroyed by preirradiation with high peak power pulsed laser
radiation at 1064 nm (Busetti et al, 1998).
At present, the studies with these photosensitizers are
progressing in order to optimize their phototherapeutic activity. On
the other hand, we found that a promising newly developed PDT
agent, benzoporphyrin derivative monoacid ring A (verteporfin,
BPD-MA), displays particularly large photosensitizing efficacy
against B16 pigmented melanoma, i.e. a heavily pigmented variety
of melanotic melanoma, in spite of the fact that its longest wave-
length absorption band peaks at 690 nm, where the transmittance
of pigmented mammalian tissues to light is still very low. This
favourable but unexpected property of BPD-MA is the subject of
the present communication.
MATERIALS AND METHODS
Female C57/BL6 mice (18–20 g body weight) obtained from
Harlan Sprague Dawley (Indianapolis, IN, USA) were used as
experimental models. B16 pigmented melanoma (the B16 cell line
was obtained from American Type Culture Collection) was subcu-
taneously transplanted into the upper flank of the mice by injecting
20 ml (106 cells) of a sterile cell suspension in phosphate-buffered
saline (PBS). The cell line was cultured in Dulbecco’s modified
minimal essential medium (Sigma) and supplemented with 10%
fetal calf serum (Boehringer Mannheim). The cell culture was
maintained at 37°C in a humidified atmosphere of 5% carbon
dioxide in air.
At 8 days after transplantation, when the tumour diameter was
about 0.6 cm, the B16 tumour-bearing mice were intravenously
injected with a liposomally formulated BPD-MA (4 mg kg–1 body
weight) obtained from Quadra Logic Technologies (Vancouver,
BC, Canada). Aliquots of BPD-MA were reconstituted from the
lyophilized powder with distilled water at a concentration of 
1.47 mg ml–1 and stored, protected from light at 4°C. Further dilu-
tions were carried out immediately before individual experiments
using 5% dextrose in water.
At predetermined times after injection, the mice were sacrificed
and the BPD-MA content in the serum and selected tissues was
determined by spectrophotofluorimetric procedures. Briefly, the
blood was centrifuged to remove the erythroctyes and appropri-
ately diluted with 2% aqueous sodium dodecyl sulphate (SDS).
The tissue specimens were homogenized in 2% SDS, the homo-
genate was tenfold diluted with a chloroform–methanol binary
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supernatant was collected and analysed for its BPD-MA content
by fluorescence spectroscopy (excitation at 400 nm, emission at
650–760 nm), using a calibration plot built with known concentra-
tions of BPD-MA in the same solvent mixture.
For the phototherapeutic studies, the tumour area was irradiated
at 3 h or 9 h after i.v. administration of BPD-MA (4 mg kg–1) using
an argon-pumped dye laser with emission at 690 nm. The fluence
rate ranged between 180 and 300 mW cm–2 for a total light fluence
of 300 or 520 J cm–2. Under these irradiation conditions, the
temperature of the tumour tissue increased to 38°C from a basal
value of 33°C; this increase is below the extent required to give
hyperthermal effects in the same animal model, as shown previ-
ously (Biolo et al, 1996). In a different set of experiments, the
tumour area of the BPD-MA injected mice was irradiated with one
pulse of 1064-nm light from a Q-switched Nd:YAG laser which
was operated in a pulsed mode (10 ns pulses, 10 Hz, energy per
pulse 650 mJ) and, immediately after, it was exposed to PDT treat-
ment. In all cases, the effectiveness of the treatment was evaluated
by comparing the rate of tumour growth of the irradiated mice
with that observed for control mice transplanted simultaneously
with the phototreated mice but not injected with BPD-MA and not
exposed to light. The tumour size was measured daily by means of
a calliper. Individual tumour volumes (V) were calculated by
assuming a hemiellipsoidal structure for the tumour nodule and
measuring the two perpendicular axes (a and b) and the height (c).
Application of the relationship V = 2/3p(a/2 ´ b/2 ´ c) provided
the tumour volume. The number of days for the tumour volume to
reach 1 cm3 was calculated for the individual tumours.
RESULTS AND DISCUSSION
The pharmacokinetic and phototherapeutic studies with C57/BL6
mice bearing the B16 pigmented melanoma were performed by i.v.
injection of 4 mg, i.e. 5.5 mmol of BPD-MA kg–1 body weight. This
dosage was chosen because previous reports (Allison et al, 1991)
have shown that this amount of BPD-MA is effective in the PDT of
other experimental tumours. Moreover, our initial investigations on
the PDT of melanotic melanoma with SiNc (Biolo et al, 1996) were
successfully carried out by administration of 0.64 mmol kg–1 photo-
sensitizer; as the extinction coefficient of SiNc and BPD-MA at the
wavelengths used for their in vivo excitation are 557 000 M–1 cm–1
(773 nm) and 33 000 M–1 cm–1 (690 nm), respectively, the injection
of an approximately 8.5-fold larger dose of BPD-MA should
compensate, at least in principle, for the lower efficiency of light
absorption. The recoveries of BPD-MA from the tumour, selected
normal tissues and serum at different post-injection times are
summarized in Table 1. The data represent the average recoveries
from three independently analysed mice. An overall examination of
the data suggests the following conclusions:
(1) BPD-MA is readily accumulated by the melanotic melanoma
reaching maximum concentrations (1.8–1.9 nmol g–1) at
1–3 h after i.v. administration. In the same animal model,
SiNc yielded largest tumour concentrations of 0.33 nmol g–1
at 24 h after injection, i.e. about 5.7-fold lower concentra-
tions than those found for BPD-MA; hence, BPD-MA
appears to be a slightly less efficient localizer of this specific
tumour, because it had been injected in 8.5-fold larger
concentrations (see above).
(2) The selectivity index of tumour targeting is given by the
ratio between the photosensitizer concentration in the
tumour to the peritumoral tissue, which is represented by the
skin in our case. We analysed the BPD-MA recovery from
skin areas adjacent and distal to the neoplastic lesion, as
melanotic melanoma is known to undergo a radial diffusion,
thereby readily infiltrating the surrounding cutaneous
districts (Wosko et al, 1994). Our findings suggest that a
limited selectivity of melanoma targeting by BPD-MA
occurs only at 1–3 h with a concentration ratio of 1.6. In
contrast, no selectivity of accumulation in the melanotic
melanoma was observed for SiNc (Biolo et al, 1994;
Biolo et al, 1996). Both BPD-MA and SiNc were found to
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Figure 1 Effect of 690-nm light irradiation (300 mW cm–2) on the rate of
tumour growth in C57/BL mice bearing a B16 pigmented melanoma, which
had been i.v. injected with BPD-MA (4 mg kg–1). Irradiations were performed
at 3 h (l) and 9 h (s) after injection. (n) Control unirradiated mice. Each
point represents the average of seven mice ± s.d.
Table 1 Recovery of BPD-MA from selected tissues (nmol g–1) and serum (nmol ml–1) of C57/BL6 mice bearing a B16 pigmented melanoma at various times
after i.v. injection of the photosensitizer (5.5 mmol kg–1).
Time Tumour Peritumoral skin Distal skin Liver Spleen Serum
30 min 0.92 ± 0.23 0.79 ± 0.12 0.65 ± 0.14 44.53 ± 9.22 1.94 ± 0.18 9.30 ± 1.77
1 h 1.94 ± 0.22 1.31 ± 0.42 0.90 ± 0.20 29.61 ± 9.34 1.38 ± 041 6.49 ± 0.94
3 h 1.86 ± 0.10 1.13 ± 0.18 0.83 ± 0.57 15.64 ± 3.05 0.40 ± 0.11 4.40 ± 0.60
6 h 1.05 ± 0.13 0.95 ± 0.22 0.72 ± 0.23 11.84 ± 1.44 0.25 ± 0.13 4.17 ± 0.86
9 h 0.93 ± 0.01 0.71 ± 0.03 0.87 ± 0.17 6.15 ± 0.91 nd 3.23 ± 0.69
24 h nd nd nd 0.89 ± 0.16 nd 0.74 ± 0.06
nd, not detectable. Values ± s.d.; three mice were independently analysed at each time.give a good selectivity of tumour targeting in other trans-
planted tumours (Cuomo et al, 1990; Richter et al, 1990).
The poor degree of selectivity observed in our experimental
model is likely to reflect the fact that the skin of C57/BL6
mice accumulates unusually high amounts of photosensi-
tizing agents.
(3) The large amount of BPD-MA recovered from liver suggests
that this drug is mainly cleared from the organism via the
bile–gut pathway, as it is typical of most liposome-delivered
dyes (Jori, 1987).
(4) BPD-MA is eliminated at a remarkably fast rate, as at 24 h
after injection residual small amounts of this porphyrin are
still present only in the liver and serum. This property of
BPD-MA is of particular importance for minimizing the
occurrence of undesired side-effects, such as long-term liver
toxicity or the persistence of generalized cutaneous photo-
sensitivity for some weeks after the PDT treatment (Marcus,
1992). In this connection, BPD-MA is superior to SiNc,
whose clearance from the organism is still incomplete
1 week after i.v. injection (Biolo et al, 1994).
On the basis of the pharmacokinetic studies, the PDT treatment
of the B16 pigmented melanoma was performed at 3 h after 
the administration of 4 mg kg–1 BPD-MA. When the irradiation
protocol involved the delivery of an overall light dose of 
520 mJ cm–2, we observed a rapid development of an extensive
necrotic area in the neoplastic mass as well as of peritumoral
oedema; this was accompanied by a marked reduction in the rate
of tumour growth as compared with that typical of control
C57/BL6 mice (Figure 1). The PDT-treated mice appeared to be
tumour free for almost 2 weeks. The delay of melanotic melanoma
regrowth, as calculated from the data plotted in Figure 1, was 28
days (Table 2). No detectable tumour response was observed when
the neoplastic lesion was exposed to 690-nm light under the same
experimental conditions but in the absence of BPD-MA.
The extent of tumour response appeared to be correlated with the
photosensitizer concentration in the malignant tissue: in fact, when
the irradiation was performed under the same experimental condi-
tions but at 9 h post injection, i.e. when the BPD-MA concentration
in the tumour was decreased by about 50% as compared with that
at 3 h, a significant response of the tumour was still observed;
however, the regrowth delay was about 14 days (Figure 1).
Similarly, a drop in the extent of tumour response to PDT took
place upon reduction of the total light fluence and the fluence rate
(Table 2). BPD-MA appears to be endowed with a high photothera-
peutic activity towards the pigmented melanoma, as the PDT of
B16 melanoma with SiNc gave a maximum delay of 4 days for
tumour regrowth when applied using optimal light/photosensitizer
doses (Biolo et al, 1996). The photoactivity of BPD-MA is similar
to that observed for Lutexaphyrin, even though the latter porphyrin
absorbs at longer wavelengths (Woodburn et al, 1997).
The effectiveness of BPD-MA was unexpected because the
available data on the optical properties of heavily pigmented
tissues, including melanotic melanoma, suggest that there is essen-
tially no light transmittance up to about 720–730 nm. All the photo-
sensitizers that so far have given positive results in the PDT of
melanotic melanoma are characterized by the presence of intense
absorption bands at wavelengths longer than 700 nm. It is possible
that an initial photoinduced damage of superficial tissue layers is
efficiently propagated throughout the tumour mass, which would
be in agreement with the observation that BPD-MA predominantly
acts by impairing the vascular system (Levy et al, 1994).
In all cases, pretreatment of the pigmented melanoma with high
peak power 1064-nm laser radiation strongly enhanced the effi-
ciency of the subsequent PDT treatment, as one can again deduce
from the tumour regrowth delay data tabulated in Table 2. The
1064 + 690 nm irradiation studies were performed under subop-
timal conditions, namely at 9 h post injection of BPD-MA. When
the same studies were repeated at 3 h post injection, corresponding
with maximal BPD-MA accumulation in the tumour, frequent
death of phototreated mice was observed. Preliminary studies
(Table 2; see also Busetti et al, 1998) showed that the Nd:YAG
irradiation of B16 pigmented melanoma induces a specific break-
down of melanosomes with a modest (3–4 days) delay of tumour
growth. Therefore, the observed enhancement of the tumour
response to PDT with BPD-MA cannot be exclusively ascribed to
the effect of the high peak power irradiation. Rather, such
enhancement could be the result of the reduced optical filtering by
the melanin pigments and the limited damage of the melanoma
vascular system, i.e. the preferential site of the BPD-MA photo-
sensitizing action. Similarly, the association of the SiNc-PDT with
photoinduced thermal effects (Biolo et al, 1996) improved the
response of B16 pigmented melanoma from a 4- to a 13-day
regrowth delay.
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Table 2 Effect of different irradiation protocols performed 9 h post-injection of BPD-MA (5.5 mmol kg–1) on regrowth of subcutaneously transplanted B16
pigmented melanoma in C57/BL6 mice (seven mice per group).
Irradiation wavelengths Irradiation parameters Tumour free time Regrowth delay
(nm) mJ/pulse + mW/cm–2 –J/cm–2 (days) (days)a
1064 650 0 3.7 ± 1.1
690b 300–520 0 0.0 ± 0.2
690c 300–520 15 28.0 ± 3.1
690 300–520 10 14.3 ± 1.0
1064 + 690 650 + 300–520 15 24.0 ± 0.9
690 300–300 0 5.0 ± 2.9
1064 + 690 650 + 300–300 7 19.5 ± 2.0
690 180–300 0 3.7 ± 2.2
1064 + 690 650 + 180–300 6 17.0 ± 0.6
aDifference between the growth time for treated and control mice. The growth time is the time interval for the tumour to grow to a volume of 1 cm3 from the size
at the time of irradiation (0.03–0.04 cm3). The growth time of control mice was 11 days. bControl mice irradiated without injection of BPD-MA. cThe irradiation
was performed 3 h post BPD-MA injection.A more precise interpretation of the present findings will hope-
fully be provided by studies on the mechanism by which BPD-MA
induces the necrosis of B16 melanotic melanoma, which are in
progress in our laboratory. In any case, our findings clearly show
that this porphyrin can also be successfully used in the treatment of
pigmented tumours, thereby extending the scope of PDT. The effi-
cacy of the phototherapeutic modality can be further enhanced by
the application of photothermal treatment immediately before PDT.
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